Protective effects of rhu TNFR: Fc against the lipopolysaccharide induced intestinal damage of rats and its underlying mechanism

Yaoxue Xuebao

Volumn 44, Issue 6, 2009, Pages 586-590

  Guo, Zhu Ying ^a   Wang, Shi Ting ^a   Xu, Mang Hua ^a   Jiao, Qiang ^a   Gao, Feng Hou ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Intestine injury; Lipopolysaccharide; Rhu TNFR: Fc; Tumor necrosis factor

Indexed keywords

ETANERCEPT; LIPOPOLYSACCHARIDE; MALONALDEHYDE; MYELOPEROXIDASE; RECOMBINANT TUMOR NECROSIS FACTOR RECEPTOR 2 FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; INTESTINE INJURY; MEAN ARTERIAL PRESSURE; MORTALITY; NONHUMAN; RAT;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; INTESTINES; LIPOPOLYSACCHARIDES; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RECOMBINANT FUSION PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 68549126938     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Huang JL, Ji JR, Zhao LK, et al. Study of effective and security of treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor-Fc fusion protein [J]. Chin Rem Clin, 2006, 6: 543-545.
2. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab [J]. J Dermatol Treat, 2004, 15:280-294. (Pubitemid 39423287)
3. Hu DW, Bao CD, Chen SL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor-Fc fusion protein: a multicenter, randomized, double blind, controlled trial [J]. Chin J Rheumatol, 2005, 9: 664-668.
4. Hassoun HT, Kone BC, Mercer DW, et al. Post-injury multiple organ failure: the role of the gut [J]. Shock, 2001, 15:1-10. (Pubitemid 33598153)
5. Jarry A, Bossard C, Bou-Hanna C, et al. Mucosal IL-10 and TGF-beta play crucial roles in preventing LPS-driven, IFN-gamma-mediated epithelial damage in human colon explants [J]. J Clin Invest, 2008, 118: 1132-1142.
6. Rivera CA, Wheeler MD, Enomoto N, et al. A choline-rich diet improves survival in a rat model of endotoxin shock [J]. Am J Physiol Gastrointest Liver Physiol, 1998, 275: G862-G867. (Pubitemid 28491844)
7. Avunduk MC, Avunduk AM, Oztekin E, et al. Etanercept treatment in the endotoxin-induced uveitis of rats [J]. Exp Eye Res, 2004, 79: 357-365. (Pubitemid 39164473)
8. Cowin AJ, Hatzirodos N, Rigden J, et al. Etanercept decreases tumor necrosis factor-alpha activity in chronic wound fluid [J]. Wound Rep Reg, 2006, 14: 421-426. (Pubitemid 44266598)
9. Deitch EA. Multiple organ failure: pathophysiology and potential future therapy [J]. Ann Surg, 1992, 216: 117-134.
10. Tang HF, Mao LG Jiang LA, et al. Protective effect against monoammonium glycyrrhizinate on lipopolysaccharide-induced acute lung injury in mice [J]. Acta Pharm Sin, 2007, 42: 954-958.
11. Su GL. Lipopolysaccharides in liver injury: molecular mechanisms of Kupffer cell activation [J]. Am J Physiol Gastrointest Liver Physiol, 2002, 283: G256-265.
12. Salvemini D, Riley DP, Cuzzocrea S. SOD mimetics are coming of age [J]. Nat Rev Drug Discov, 2002, 1: 367-374. (Pubitemid 37361466)